VSTM Verastem, Inc.
Executive Summary
Seven institutional investors accumulated $4.2M net in Verastem (VSTM) in Q3 2024, led by Alyeska Investment Group more than doubling its position to $5.6M, while Citadel nearly exited. The strong buy-side conviction from multiple active managers suggests a shared thesis on the clinical pipeline, but the small absolute dollar amounts and the company's history of stock declines warrant cautious interpretation.
Key Financial Metrics
Institutional Positions
Net institutional flow: $4.2M
▲ Buyers (7)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Alyeska Investment Group | DOUBLED | +165.7% | $5.6M | $3.5M |
| Walleye Capital | DOUBLED | +493.7% | $646.0K | $538.0K |
| Stifel Financial | ADD | +62.3% | $91.0K | $35.0K |
| Legal & General Group | ADD | +71.7% | $14.0K | $6.0K |
| Schwab | ADD | +46.3% | $310.0K | $99.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | NEAR_EXIT | -90.4% | $91.0K | -$81.8K |
Actionable Insight
The cluster is directionally bullish but small in absolute dollars for a biotech micro-cap. Monitor upcoming pipeline catalysts (clinical trial readouts, regulatory updates) that may validate the accumulation thesis. The historical poor performance of prior neutral calls on VSTM suggests the stock has been declining; this cluster may represent bottom-fishing by active managers, but conviction should be tempered until price action confirms.
Key Facts
- 7 buyers accumulated net $4.2M in VSTM during Q3 2024 (current holdings $6.7M), versus 1 seller reducing by $82K
- Alyeska Investment Group more than doubled its stake, adding $3.5M (current value $5.6M), representing ~84% of total buying activity
- Walleye Capital nearly quintupled its shares (+493.7%), adding $538K
- Citadel reduced its position by 90.4%, exiting nearly completely with remaining $9K
- Historical 13F cluster analysis on VSTM shows poor accuracy (0% win rate at T+20, avg -12.6%) but based on only 2 settled observations
Financial Impact
Net institutional accumulation of $4.2M (total buyer current holdings $6.7M) across 7 funds, with one seller reducing by $82K. The largest move came from Alyeska Investment Group adding $3.5M.
Risk Factors
- Small dollar amounts ($6.7M total) limit the signal's market impact
- Historical analysis shows VSTM institutional cluster calls have underperformed (0% win rate at T+20, n=2)
- 13F data is 45+ days stale; positions may have already been adjusted
- Clinical-stage biotech risk: single trial failure could erase value regardless of ownership changes
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-VSTM-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $3.94 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $3.76 awaiting T+5 | awaiting T+5 | — | — |
|
May 27, 2026
16d ago
|
3
| $4.29 $3.86 | ▼ −10.02% | ▼ −10.34% | — |
|
May 27, 2026
16d ago
|
144
| $4.29 $3.62 | ▼ −15.62% | ▼ −15.57% | — |
|
Mar 4, 2026
14w ago
|
8-K
| $6.15 $5.84 | ▼ −5.04% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access